| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.37 | 1e-06 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.31 | 3e-06 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.21 | 0.003 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.005 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.009 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.66 | 0.01 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.08 | 0.01 |